Lists of diseases

Amryt Supports Global EB Awareness Week 2022

Retrieved on: 
Monday, October 24, 2022
Lists of diseases, Caregiver, Disease, Hope, EMA, Sibling, Lipodystrophy, Acromegaly, Metreleptin, Parent, Patient, List of minor secular observances, AIM, Investment, Awareness, Degenerative disease, Lomitapide, Birth, EB, CEO, Environment, European, Diet, GL, Forward-looking statement, FDA, CHMP, COVID-19, Octreotide, Pharmaceutical industry, Dietary supplement, EU

DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support for Global Epidermolysis Bullosa (EB) Awareness Week which is taking place October 25 - 31, 2022.

Key Points: 
  • DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support for Global Epidermolysis Bullosa (EB) Awareness Week which is taking place October 25 - 31, 2022.
  • Amryt is committed to transforming the lives of people affected by rare, debilitating conditions like EB by bringing new treatment options to those in need.
  • EB Awareness Week represents an important opportunity to raise visibility of this devastating condition and the need for expanded treatment options.
  • EB Awareness weekis an important time to increase awareness of the disease, the need for direct support and for commercially available treatments.

Saudi Arabia Hospital (General, Specialty, Multi-Speciality) Markets, Analysis, Competition, Forecasts & Opportunities, 2028F - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 26, 2022
Health, Hospitals, Quality of life, Government, Growth, Drug development, General officer, Berenson-Eggers Type of Service, Research, Investment, Ownership, Diabetes, Privatization, Degenerative disease, Lists of diseases, Tobacco, Weapon, Health insurance, Oil, Type

Growing presence of advanced diagnostic technology and rising innovations in the drug development are contributing to the Saudi Arabia hospital market growth significantly.

Key Points: 
  • Growing presence of advanced diagnostic technology and rising innovations in the drug development are contributing to the Saudi Arabia hospital market growth significantly.
  • Increased investments by the government to enhance healthcare infrastructure in the country and improved quality and service for better outcomes are boosting the growth of Saudi Arabia hospital market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Saudi Arabia hospital market.
  • Company Profiles: Detailed analysis of the major companies present in Saudi Arabia hospital market.

India $885+ Mn Minimally Invasive Surgical Devices Markets, Analysis, Competition, Opportunity, and Forecasts, 2027F - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 26, 2022
Surgery, Health, Adoption, Pelvic pain, Disease, City, Prevalence, Growth, CAGR, Gynaecology, Patient, Hospital, Research, Anovulation, Cancer, Degenerative disease, Paniki (cutting instrument), Competition, Conditional sentence, Gastrointestinal bleeding, Menstruation, Lists of diseases, Endometriosis, Medical device, Birth control, Motor vehicle

are also supporting the growth of the Indian Minimally Invasive Surgical Devices Market in the next five years.

Key Points: 
  • are also supporting the growth of the Indian Minimally Invasive Surgical Devices Market in the next five years.
  • Minimally invasive procedures are also used in uterus removal surgeries, thereby fueling the demand for different minimally invasive surgical devices along with the market growth.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Indian Minimally Invasive Surgical Devices Market.
  • To identify key sustainable strategies adopted by the market players in the Indian Minimally Invasive Surgical Devices Market.

Global Diagnostic Imaging Services Market Report 2022: Early Disease Detection and Rising Incidence of Age-Associated Diseases to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 26, 2022
Data Management, Health, Technology, General Health, Radiology, Biotechnology, Adoption, Hierarchy, Insurance, Growth, Population, Neurodegeneration, CAGR, Cardiology, APAC, Hospital, Medical tourism, Workforce, Abdomen, Lists of diseases, Investment, MRI, Google Images, Awareness, Incidence, Conditional sentence, Midsayap Diagnostic Center and Hospital, Brain damage, Elective surgery, USD, Medical imaging, Technology, Modality, Mammography, Neurology, Ultrasound

The diagnostic imaging services market is projected to reach USD 702.6 billion by 2027 from USD 549.0 billion in 2022, at a CAGR of 5.1% during the forecast period.

Key Points: 
  • The diagnostic imaging services market is projected to reach USD 702.6 billion by 2027 from USD 549.0 billion in 2022, at a CAGR of 5.1% during the forecast period.
  • Major factors driving the growth of the market includes rising global incidence of various chronic diseases, growing awareness about the different imaging modalities, and growing expansion of outpatient imaging centers.
  • In 2021, the x-ray segment accounted for the largest share of the diagnostic imaging services market.
  • The diagnostic imaging services market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East & Africa.

AMRA Medical at AASLD 2022: Premier MRI Technology and Informatics for The Full Continuum of Liver Disease

Retrieved on: 
Wednesday, October 26, 2022
Medical Supplies, Biotechnology, Professional Services, Health, General Health, Venture Capital, Biometrics, Health Technology, Medical Devices, Research, Science, BCP, Disease, Therapy, Informatics, Liver disease, Risk, Clinical study design, Non-alcoholic fatty liver disease, NAFLD, Patient, Research, Multimedia, MRI, Technology, Mass, Sarcopenia, CEO, Cirrhosis, Liver, Lists of diseases, 2021 Essex County Council election, Frailty, Chronic liver disease, FDA, Conditional sentence, Solution, Scan, Magnetic resonance imaging, Medical imaging, Dietary supplement, Dentistry

AMRA Medical , and their collaborators, will present seven abstracts along the whole disease progression line of chronic liver disease, with studies involving individuals with early liver disease (non-alcoholic fatty liver disease; NAFLD) to cirrhosis to liver transplant.

Key Points: 
  • AMRA Medical , and their collaborators, will present seven abstracts along the whole disease progression line of chronic liver disease, with studies involving individuals with early liver disease (non-alcoholic fatty liver disease; NAFLD) to cirrhosis to liver transplant.
  • View the full release here: https://www.businesswire.com/news/home/20221026005321/en/
    AMRA Medicals MRI-based technology and informatics are featured in seven abstracts accepted for presentation at The Liver Meeting 2022 the worlds must-attend hepatology meeting.
  • Two abstracts involving individuals with early liver disease and the potential to risk stratify based on muscle composition will be presented.
  • Attend the abstract presentations or visit our booth #731 to learn more about the utility of AMRAs technology in liver disease research and in the clinic.

Octave Commercially Launches a First-in-Class Precision Care Solution for Multiple Sclerosis

Retrieved on: 
Wednesday, October 26, 2022
Health, Health Technology, Time, Disease, Missouri Baptist Medical Center, MS, Population, Multiple sclerosis, Magnetic resonance imaging, Neurodegeneration, Patient, Biology, Lists of diseases, Research, MRI, University of Michigan Institute for Social Research, Medical director, Neurology, Decision-making, Drug discovery, MD, Health, DO, CEO, Ecosystem, MIND, ER, CMSC, Center, American Neurological Association, Biomarker, Medical imaging, Medical device, Pharmaceutical industry, Hospital, Medicine, Octave

Octave , a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced that its precision care solution for MS is now commercially available.

Key Points: 
  • Octave , a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced that its precision care solution for MS is now commercially available.
  • We are thrilled to be offering the MS community our Precision Care Solution, for which we have completed validation studies and continue to advance, said William Hagstrom, Founder and CEO of Octave.
  • Octave was founded to deliver a precision care solution for multiple sclerosis as well as a full range of neurodegenerative diseases.
  • Octaves Precision Care Solution is the first-of-its-kind that accurately and objectively measures, and helps manage, complex and high-cost neurodegenerative diseases, starting with multiple sclerosis.

Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Wednesday, October 26, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Psoriasis, Therapy, Amgen, Multiple sclerosis, Drug, Lists of diseases, Multiple sclerosis research, Patient, MBA, Research, Senior, Cancer, University, University of Connecticut School of Medicine, Medical Affairs Bureau, HPK1, Board, Degenerative disease, TYK2, Leadership, Pharmaceutical industry, Biogen, Nimbus

Nimbus Therapeutics , a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the appointment of Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Nimbus Therapeutics , a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the appointment of Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer.
  • I am delighted to welcome Nathalie to our leadership team as Nimbus advances multiple potential breakthrough candidates into their next phase of development, including our clinical TYK2 and HPK1 inhibitors, said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus.
  • Dr. Franchimont joins Nimbus from Biogen, where she served as Senior Vice President, Head of Multiple Sclerosis and Immunology Development Unit.
  • Prior to joining Biogen, Dr. Franchimont held Medical Affairs and Clinical Development roles at Amgen.

Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Lists of diseases, RXRA, Disease, Therapy, Squamous cell carcinoma, IND, Factor X, Neoplasm, Biotechnology, Bladder cancer, Patient, Biology, Inflammation, Cancer, Drug discovery, Neurology, Incidence, Breast, Retinoid X receptor alpha, Prostate cancer, Recurrence, Third Rock Ventures, Gene silencing, Gene, Pharmaceutical industry, Medical imaging, PPARG, Flare, UC

Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.

Key Points: 
  • Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.
  • In preclinical models, FTX-6746 demonstrated a favorable therapeutic profile, suppressing PPARG target genes with durable tumor regression at well-tolerated doses.
  • Flare is poised to transition to a clinical-stage company early next year with our lead molecule in the PPARG program.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Managed Care, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Immunology, Congress, Merck, RNA transfection, Multiple sclerosis, Science, OLE, MRI, University, Treatment, Hypoesthesia, Infertility, Antigen, Biomarker, SEL, MS, Gene editing, HIV disease progression rates, DBP, Inflammation, Learning, Senior, Cancer, Company, AFL, EMD, Phase, Central nervous system, Merck Millipore, BTK, Health care, Electronics, Lists of diseases, Intelligence, Research, Nerve, Microglia, CNS, ARR, European Committee of the Regions, Merck Serono, Disease, Life, Patient, EDSS, MD, Doctor of Philosophy, Â, RMS, University of Lille, Merck Group, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.

Global Long Read Sequencing Market Report 2022: Potential Applications In Clinical Sequencing And Analysis Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Health, Biotechnology, Adoption, Lists of diseases, Prevalence, LRS, Severe acute respiratory syndrome coronavirus 2, CAGR, Research, Coronavirus, D, Knowledge, Industry, SMRT, Application, WGS, DNA, Workflow, Map, Oxford Nanopore Technologies, COVID-19, USD, Pharmaceutical industry, Technology

The "Long Read Sequencing Market Size, Share & Trends Analysis Report by Technology (SMRT Sequencing), by Product, by Application, by Workflow, by End Use, Region and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Long Read Sequencing Market Size, Share & Trends Analysis Report by Technology (SMRT Sequencing), by Product, by Application, by Workflow, by End Use, Region and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global long read sequencing market size is expected to reach USD 4.53 billion by 2030, registering a CAGR of 14.74%, according to this report.
  • Since the sequencing method has shown to be of utmost importance in modifying pharmaceuticals, there is also a cumulative market value for the expanding knowledge of long read sequencing.
  • An increase in the adoption of these technologies for the analysis of structural variants is expected to drive the market throughout the forecast period.